Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in Uganda.
Amutuhaire W, Semitala FC, Kimera ID, Namugenyi C, Mulindwa F, Ssenyonjo R, Katwesigye R, Mugabe F, Mutungi G, Ssinabulya I, Schwartz JI, Katahoire AR, Musoke LS, Yendewa GA, Longenecker CT, Muddu M. Amutuhaire W, et al. Among authors: mulindwa f. J Hum Hypertens. 2024 May;38(5):452-459. doi: 10.1038/s41371-024-00897-3. Epub 2024 Feb 1. J Hum Hypertens. 2024. PMID: 38302611 Free PMC article.
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report.
Mulindwa F, Castelnuovo B, Brusselaers N, Bollinger R, Yendewa G, Amutuhaire W, Mukashaka C, Schwarz JM. Mulindwa F, et al. Res Sq [Preprint]. 2023 Aug 25:rs.3.rs-3218404. doi: 10.21203/rs.3.rs-3218404/v1. Res Sq. 2023. Update in: BMC Infect Dis. 2023 Oct 30;23(1):744. doi: 10.1186/s12879-023-08712-z PMID: 37674704 Free PMC article. Updated. Preprint.
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks.
Mulindwa F, Schwarz JM, Brusselaers N, Nabwana M, Bollinger R, Buzibye A, Amutuhaire W, Yendewa G, Laker E, Kiguba R, Castelnuovo B. Mulindwa F, et al. Res Sq [Preprint]. 2023 Aug 3:rs.3.rs-3154716. doi: 10.21203/rs.3.rs-3154716/v1. Res Sq. 2023. Update in: BMC Infect Dis. 2024 Jul 29;24(1):746. doi: 10.1186/s12879-024-09655-9 PMID: 37577475 Free PMC article. Updated. Preprint.
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults.
Mulindwa F, Castelnuovo B, Brusselaers N, Nabwana M, Bollinger R, Laker E, Kiguba R, Schwarz JM. Mulindwa F, et al. Res Sq [Preprint]. 2023 Jul 20:rs.3.rs-3175598. doi: 10.21203/rs.3.rs-3175598/v1. Res Sq. 2023. Update in: AIDS Res Ther. 2023 Sep 9;20(1):65. doi: 10.1186/s12981-023-00564-6 PMID: 37502917 Free PMC article. Updated. Preprint.
Implementation of longitudinal insulin kinetic studies in busy field settings in Uganda: experience from the "glucose metabolism changes in Ugandan HIV patients on dolutegravir based anti-retroviral therapy" (GLUMED study).
Mulindwa F, Schwarz JM, Brusselaers N, Dujanga S, Yendewa G, Castelnuovo B. Mulindwa F, et al. Pan Afr Med J. 2023 Apr 19;44:184. doi: 10.11604/pamj.2023.44.184.39734. eCollection 2023. Pan Afr Med J. 2023. PMID: 37484585 Free PMC article. No abstract available.
19 results